Cluster,market,Value_MS_Change,Value_Growth,Volume_MS_Change,Volume_Growth,ASP_Growth,region
Endo NA,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,NA
FE NA,FSH/hMG Market,1.5,0.03,1.5,0.03,0.03,NA
EUROPE,FSH/hMG Market,1.5,0.03,1.5,0.03,0.03,EU
EU5,FSH/hMG Market,1.5,0.03,1.5,0.03,0.03,EU
Mid-EU,FSH/hMG Market,1.5,0.03,1.5,0.03,0.03,EU
EUROPE,MS High Efficacy Market,1.5,0.03,1.5,0.03,0.03,EU
EU5,MS High Efficacy Market,1.5,0.03,1.5,0.03,0.03,EU
Mid-EU,MS High Efficacy Market,1.5,0.03,1.5,0.03,0.03,EU
EUROPE,Beta Blocker Market,1.5,0.03,1.5,0.03,0.03,EU
EU5,Beta Blocker Market,1.5,0.03,1.5,0.03,0.03,EU
Mid-EU,Beta Blocker Market,1.5,0.03,1.5,0.03,0.03,EU
EUROPE,Antihypertensive Combo Market,1.5,0.03,1.5,0.03,0.03,EU
EU5,Antihypertensive Combo Market,1.5,0.03,1.5,0.03,0.03,EU
Mid-EU,Antihypertensive Combo Market,1.5,0.03,1.5,0.03,0.03,EU
EUROPE,Hypothyroid Market,1.5,0.03,1.5,0.03,0.03,EU
EU5,Hypothyroid Market,1.5,0.03,1.5,0.03,0.03,EU
Mid-EU,Hypothyroid Market,1.5,0.03,1.5,0.03,0.03,EU
EUROPE,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,EU
EU5,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,EU
Mid-EU,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,EU
EUROPE,Anti-EGFR Market,1.5,0.03,1.5,0.03,0.03,EU
EU5,Anti-EGFR Market,1.5,0.03,1.5,0.03,0.03,EU
Mid-EU,Anti-EGFR Market,1.5,0.03,1.5,0.03,0.03,EU
Endo Europe,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,EU
NIM Europe,Injectable Platform Market,1.5,0.03,1.5,0.03,0.03,EU
NIM Europe,MS High Efficacy Market,1.5,0.03,1.5,0.03,0.03,EU
CV Europe,Beta Blocker Market,1.5,0.03,1.5,0.03,0.03,EU
THY Europe,Hypothyroid Market,1.5,0.03,1.5,0.03,0.03,EU
THY Europe,Hyperthyroid Market,1.5,0.03,1.5,0.03,0.03,EU
Endo LATAM,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,LATAM
NIM LATAM,Injectable Platform Market,1.5,0.03,1.5,0.03,0.03,LATAM
NIM LATAM,MS High Efficacy Market,1.5,0.03,1.5,0.03,0.03,LATAM
CV LATAM,Beta Blocker Market,1.5,0.03,1.5,0.03,0.03,LATAM
THY LATAM,Hypothyroid Market,1.5,0.03,1.5,0.03,0.03,LATAM
APAC Total,FSH/hMG Market,1.5,0.03,1.5,0.03,0.03,APAC
APAC Total wo IN,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,APAC
APAC MS Cluster,Injectable Platform Market,1.5,0.03,1.5,0.03,0.03,APAC
APAC HE MS Cluster,MS High Efficacy Market,1.5,0.03,1.5,0.03,0.03,APAC
APAC Direct Cluster,Beta Blocker Market,1.5,0.03,1.5,0.03,0.03,APAC
APAC Direct Cluster wo IN,Antihypertensive Combo Market,1.5,0.03,1.5,0.03,0.03,APAC
APAC Direct Cluster wo IN,Hypothyroid Market,1.5,0.03,1.5,0.03,0.03,APAC
APAC Hyperthyroid Cluster,Hyperthyroid Market,1.5,0.03,1.5,0.03,0.03,APAC
APAC METi Cluster wo IN,MET Inhibitor Market,1.5,0.03,1.5,0.03,0.03,APAC
APAC Anti-EGFR Cluster,Anti-EGFR Market,1.5,0.03,1.5,0.03,0.03,APAC
Endo APAC,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,APAC
THY APAC,Hypothyroid Market,1.5,0.03,1.5,0.03,0.03,APAC
NIM APAC,MS High Efficacy Market,1.5,0.03,1.5,0.03,0.03,APAC
NIM APAC,Injectable Platform Market,1.5,0.03,1.5,0.03,0.03,APAC
THY APAC,Hyperthyroid Market,1.5,0.03,1.5,0.03,0.03,APAC
CV APAC,Beta Blocker Market,1.5,0.03,1.5,0.03,0.03,APAC
Endo MEAR,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,MEAR
NIM MEAR,MS High Efficacy Market,1.5,0.03,1.5,0.03,0.03,MEAR
NIM MEAR,Injectable Platform Market,1.5,0.03,1.5,0.03,0.03,MEAR
CV MEAR,Beta Blocker Market,1.5,0.03,1.5,0.03,0.03,MEAR
Endo Global,Growth Hormone Market,1.5,0.03,1.5,0.03,0.03,Global